Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials

Deborah Hinnen,1 Davida F Kruger2 1Department of Health and Wellness, Memorial Hospital Diabetes Center, University of Colorado Health, Colorado Springs, CO 80909, USA; 2Henry Ford Health System, Division of Endocrinology, Diabetes, Bone and Mineral Disease, Henry Ford Medical Center – New...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hinnen D, Kruger DF
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Cardiovascular disease chronic disease management type 2 diabetes mellitus nurse practitioners Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/e201ad0b5d9b4b599fbfa9c4eab0843d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e201ad0b5d9b4b599fbfa9c4eab0843d
record_format	dspace
spelling	oai:doaj.org-article:e201ad0b5d9b4b599fbfa9c4eab0843d2021-12-02T08:14:22ZCardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials1178-7007https://doaj.org/article/e201ad0b5d9b4b599fbfa9c4eab0843d2019-04-01T00:00:00Zhttps://www.dovepress.com/cardiovascular-risks-in-type-2-diabetes-and-the-interpretation-of-card-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Deborah Hinnen,1 Davida F Kruger2 1Department of Health and Wellness, Memorial Hospital Diabetes Center, University of Colorado Health, Colorado Springs, CO 80909, USA; 2Henry Ford Health System, Division of Endocrinology, Diabetes, Bone and Mineral Disease, Henry Ford Medical Center – New Center One, Detroit, MI 48202, USA Background: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is paramount to determine the relationship between these two diseases. Purpose: Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug Administration published guidance for manufacturers on antihyperglycemic agents, requiring studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents have conducted and published results from CV outcomes trials (CVOTs), with more trials due to publish soon. This review discusses the relationship between CVD and T2D and explores findings from the latest CVOTs of glucose-lowering agents to guide nurse practitioners in their prescribing patterns for patients with T2D. Conclusion: Patients with T2D are at high risk of CVD, so CV risk should be carefully considered when managing these patients, and CV risks and benefits of antidiabetic drugs should be included in prescribing decisions. Keywords: cardiovascular disease, chronic disease management, type 2 diabetes mellitus, nurse practitionersHinnen DKruger DFDove Medical PressarticleCardiovascular diseasechronic disease managementtype 2 diabetes mellitusnurse practitionersSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 12, Pp 447-455 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Cardiovascular disease chronic disease management type 2 diabetes mellitus nurse practitioners Specialties of internal medicine RC581-951
spellingShingle	Cardiovascular disease chronic disease management type 2 diabetes mellitus nurse practitioners Specialties of internal medicine RC581-951 Hinnen D Kruger DF Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
description	Deborah Hinnen,1 Davida F Kruger2 1Department of Health and Wellness, Memorial Hospital Diabetes Center, University of Colorado Health, Colorado Springs, CO 80909, USA; 2Henry Ford Health System, Division of Endocrinology, Diabetes, Bone and Mineral Disease, Henry Ford Medical Center – New Center One, Detroit, MI 48202, USA Background: Patients with type 2 diabetes (T2D) are at increased cardiovascular (CV) risk compared to subjects without diabetes, with some data estimating that CV disease (CVD) risk is doubled in these individuals. Additionally, CVD remains the leading cause of death in patients with T2D, so it is paramount to determine the relationship between these two diseases. Purpose: Older diabetes treatments have limited CV safety data. In 2008, the US Food and Drug Administration published guidance for manufacturers on antihyperglycemic agents, requiring studies to ensure CV safety of new therapies. Since then, manufacturers of many newer agents have conducted and published results from CV outcomes trials (CVOTs), with more trials due to publish soon. This review discusses the relationship between CVD and T2D and explores findings from the latest CVOTs of glucose-lowering agents to guide nurse practitioners in their prescribing patterns for patients with T2D. Conclusion: Patients with T2D are at high risk of CVD, so CV risk should be carefully considered when managing these patients, and CV risks and benefits of antidiabetic drugs should be included in prescribing decisions. Keywords: cardiovascular disease, chronic disease management, type 2 diabetes mellitus, nurse practitioners
format	article
author	Hinnen D Kruger DF
author_facet	Hinnen D Kruger DF
author_sort	Hinnen D
title	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_short	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_full	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_fullStr	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_full_unstemmed	Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
title_sort	cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/e201ad0b5d9b4b599fbfa9c4eab0843d
work_keys_str_mv	AT hinnend cardiovascularrisksintype2diabetesandtheinterpretationofcardiovascularoutcometrials AT krugerdf cardiovascularrisksintype2diabetesandtheinterpretationofcardiovascularoutcometrials
_version_	1718398633239379968

Cardiovascular risks in type 2 diabetes and the interpretation of cardiovascular outcome trials

Ejemplares similares